| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20031236 | HPV | ENSG00000157764.14 | protein_coding | BRAF | Yes | No | 673 | P15056 |
| TVIS20062319 | HPV | ENSG00000157764.14 | protein_coding | BRAF | Yes | No | 673 | P15056 |
| TVIS44029013 | HTLV-1 | ENSG00000157764.14 | protein_coding | BRAF | Yes | No | 673 | P15056 |
| TVIS44025844 | HTLV-1 | ENSG00000157764.14 | protein_coding | BRAF | Yes | No | 673 | P15056 |
| TVIS44045695 | HTLV-1 | ENSG00000157764.14 | protein_coding | BRAF | Yes | No | 673 | P15056 |
| TVIS44045694 | HTLV-1 | ENSG00000157764.14 | protein_coding | BRAF | Yes | No | 673 | P15056 |
| TVIS44039660 | HTLV-1 | ENSG00000157764.14 | protein_coding | BRAF | Yes | No | 673 | P15056 |
| TVIS44039659 | HTLV-1 | ENSG00000157764.14 | protein_coding | BRAF | Yes | No | 673 | P15056 |
| TVIS44039369 | HTLV-1 | ENSG00000157764.14 | protein_coding | BRAF | Yes | No | 673 | P15056 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | BRAF |
|---|---|
| DrugBank ID | DB00398 |
| Drug Name | Sorafenib |
| Target ID | BE0000634 |
| UniProt ID | P15056 |
| Regulation Type | inhibitor |
| PubMed IDs | 16609060; 16901402; 17575107; 16880785; 20812347; 11752352; 20586710 |
| Citations | Flaherty KT: Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2366s-2370s.@@Haluska FG, Ibrahim N: Therapeutic targets in melanoma: map kinase pathway. Curr Oncol Rep. 2006 Sep;8(5):400-5.@@Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA, El-Naggar AK, Myers JN: Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther. 2007 Jun;6(6):1785-92.@@Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ: Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006 Sep 4;95(5):581-6. Epub 2006 Aug 1.@@Lu X, Tang X, Guo W, Ren T, Zhao H: Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. J Surg Oncol. 2010 Dec 1;102(7):821-6. doi: 10.1002/jso.21661.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Iyer R, Fetterly G, Lugade A, Thanavala Y: Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother. 2010 Aug;11(11):1943-55. doi: 10.1517/14656566.2010.496453. |
| Groups | Approved; Investigational |
| Direct Classification | Diarylethers |
| SMILES | CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1 |
| Pathways | Sorafenib Metabolism Pathway |
| PharmGKB | PA7000 |
| ChEMBL | CHEMBL1336 |
